---
title: How comparable are patient outcomes in the "real-world" with populations studied
  in pivotal AML trials?
date: '2024-03-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38531863/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240327180738&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Despite an increasing desire to use historical cohorts as "synthetic"
  controls for new drug evaluation, limited data exist regarding the comparability
  of real-world outcomes to those in clinical trials. Governmental cancer data often
  lacks details on treatment, response, and molecular characterization of disease
  sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer
  Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow
  cytometry, ...
disable_comments: true
---
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, ...